DOMA Perpetual Capital beneficially owns approximately 4.2% of the outstanding shares of common stock of Pacira (PCRX) BioSciences. DOMA announced its nomination of three highly skilled director candidates to Pacira BioSciences Board of Directors: Joseph Kromholz, Philip Pucciarelli and Eric de Armas. DOMA believes electing these nominees is critical to address the Board’s lack of financial sophistication and legal expertise and to correct its value-destroying capital allocation strategy. These candidates possess significant, relevant experience and are prepared to ensure that shareholders’ interests are fully represented on the Board.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira reports inducement grants under Nasdaq listing rule
- PCRX Lawsuit Alert! Class Action Lawsuit Against Pacira Biosciences, Inc.
- Pacira BioSciences Reports Record Revenues and Strategic Growth
- Pacira price target raised to $24 from $17 at Barclays
- Pacira price target raised to $22 from $18 at RBC Capital